文献速递认知障碍与谵妄老年慢病共病管理

阿司匹林降低老年2型糖尿病患者痴呆风险呈剂量依赖性

Dose-Dependent Effect of Aspirin Use in Reducing Diabetes-Associated Dementia Risk Among Elderly Patients With Type 2 Diabetes Mellitus.
PubMed 文献 · J Am Med Dir Assoc · 2024-04-18

该队列研究评估老年2型糖尿病患者中阿司匹林使用与糖尿病相关痴呆的关联。阿司匹林使用者痴呆风险显著降低(aHR 0.44,95% CI 0.41-0.46),每日强度0.91 DDD时aHR最低,累积剂量呈剂量反应关系。

要点

  • 老年2型糖尿病者用阿司匹林与痴呆风险降低相关,aHR 0.44(95% CI 0.41-0.46)。
  • 每日0.91 DDD时痴呆aHR最低,更高日剂量aHR逐渐升高但仍<1。
  • 累积DDD四分位分析呈剂量反应关系,P for trend < .0001。

核心结论

  • 老年2型糖尿病患者使用阿司匹林可显著降低痴呆风险,且呈剂量依赖性。

研究设计与样本

  • 基于人群样本的队列研究,比较阿司匹林使用者与非使用者的痴呆发生率。
  • 研究对象为≥60岁老年2型糖尿病患者。
  • 采用时变Cox风险模型评估痴呆发生风险。

主要发现

  • 老年阿司匹林使用者痴呆风险显著降低,aHR 0.44(95% CI 0.41-0.46)。
  • 每日强度0.91 DDD时痴呆aHR最低,更高日剂量(>0.91 DDD)aHR逐渐升高但仍<1。
  • 累积DDD四分位分析显示剂量反应关系,第4、3、2、1四分位aHR分别为0.16、0.42、0.57、0.63(P for trend < .0001)。

关键数值与推荐

  • 每日阿司匹林强度0.91 DDD与最低痴呆aHR相关。
  • 累积DDD越高,aHR越低,呈剂量反应关系(P for trend < .0001)。

临床怎么用

  • 对老年2型糖尿病患者评估痴呆风险时,可考虑阿司匹林使用的潜在保护关联。
  • 阿司匹林每日强度0.91 DDD与最低痴呆aHR相关,更高日剂量未见额外获益。
  • 累积剂量越高痴呆aHR越低,支持较高累积剂量可能带来获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study investigated the association between aspirin use and diabetes-associated dementia in older patients with type 2 diabetes mellitus (T2DM), assessing aspirin's potential protective effects, intensity of use, and dose-dependency against dementia. DESIGN: A cohort study evaluating the dose-dependent protective impact of aspirin against dementia in a population-based sample. SETTING AND PARTICIPANTS: Older patients with T2DM (≥60 years), comparing aspirin users with nonusers. METHODS: Used a time-varying Cox hazards model to assess dementia incidence. RESULTS: Older aspirin users exhibited a significant reduction in dementia risk (adjusted hazard ratio [aHR], 0.44; 95% CI, 0.41-0.46). The lowest aHRs for dementia were observed at a daily intensity of 0.91 defined daily doses (DDDs), and higher daily dosages (>0.91 DDD) showed gradually increasing aHRs (although still <1). Analysis of cumulative DDD revealed a dose-response relationship, with progressively lower aHRs across quartiles (0.16, 0.42, 0.57, and 0.63 for quartiles 4, 3, 2, and 1, respectively) compared with never aspirin users (P for trend < .0001). CONCLUSIONS AND IMPLICATIONS: Aspirin use in older patients with T2DM significantly reduces dementia risk. The optimal daily intensity of aspirin use (0.91 DDD) is associated with the lowest aHR for dementia. These findings suggest a dose-dependent relationship, supporting the potential benefits of higher cumulative dosages of aspirin in reducing dementia risk in this population.

来源:J Am Med Dir Assoc,查看原文。版权归原作者所有。

引用

  1. Sun M, Chen WM, Wu SY, et al. Dose-Dependent Effect of Aspirin Use in Reducing Diabetes-Associated Dementia Risk Among Elderly Patients With Type 2 Diabetes Mellitus. J Am Med Dir Assoc. 2024. PMID: 38642589. doi:10.1016/j.jamda.2024.03.110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。